Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

HEART FAILURE

HDACs as a therapeutic target in HFpEF

Nature Reviews Cardiology volume 17, page 132 (2020)Cite this article

Subjects

New research suggests that histone deacetylase (HDAC) inhibition might improve cardiopulmonary structure and function in heart failure with preserved ejection fraction (HFpEF). In a cat model of slow-progressive, pressure overload-induced diastolic dysfunction, which recapitulates features of human HFpEF, daily treatment with the pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) for 2 months reduced left ventricular (LV) hypertrophy and left atrial size, increased myofibril relaxation ex vivo and LV relaxation in vivo, and improved LV systolic and diastolic function and pulmonary structure and function compared with vehicle-treated cats. Mechanistically, SAHA treatment reduced the acetylation of mitochondrial metabolic enzymes, leading to increased mitochondrial respiration. These results suggest that HDAC inhibition with SAHA, which has FDA approval for the treatment of cutaneous T cell lymphoma, might be beneficial for improving adverse cardiopulmonary remodelling in HFpEF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Wallner, M. et al. HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. Sci. Transl Med. 12, eaay7205 (2020)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cardiology http://www.nature.com/nrcardio/

    Irene Fernández-Ruiz

Authors
  1. Irene Fernández-Ruiz
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Irene Fernández-Ruiz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernández-Ruiz, I. HDACs as a therapeutic target in HFpEF. Nat Rev Cardiol 17, 132 (2020). https://doi.org/10.1038/s41569-020-0335-6

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41569-020-0335-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing